AngioDynamics (ANGO) Falls -26.8% Over 30 Days After Earnings and Leadership Update
Key Takeaways
- AngioDynamics shares fell roughly 26.8% over the last 30 days, from $15.22 on September 8 to about $11.14, with most of the decline arriving after the company's fiscal first-quarter report.
- The company beat fiscal Q1 2027 revenue and adjusted EPS estimates yet still posted a GAAP loss, and the stock dropped more than 20% in the session following the results.
- AngioDynamics announced a leadership change: Eric Honroth becomes president and chief executive officer effective November 2, 2026, succeeding retiring CEO Jim Clemmer.
- Med Tech momentum remained strong, with revenue up 13.2% and Auryon recording its 21st consecutive quarter of double-digit growth.
- Management reiterated full-year fiscal 2027 guidance of $336 million to $341 million in revenue and $13 million to $16 million in adjusted EBITDA.
AngioDynamics (ANGO) Business Overview and Strategic Shift
AngioDynamics, Inc. develops and sells minimally invasive, image-guided medical devices aimed at restoring blood flow, treating peripheral vascular disease, and supporting cancer therapies. The company reports results through two segments: Med Tech, which covers the Auryon atherectomy system, AngioVac and AlphaVac thrombus platforms, and the NanoKnife oncology system; and Med Device, focused on vascular access, venous products, ports, and related oncology items.
The firm has been tilting its revenue mix toward higher-growth Med Tech offerings. Those platforms accounted for 49% of total revenue in the most recent quarter, up from 47% a year earlier. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track the name for its Med Tech execution, the route to sustained profitability, and upcoming clinical and reimbursement developments in atherectomy, thrombectomy, and ablation.
ANGO Stock Performance Over the Past 30 Days and Quarter
ANGO declined about 26.8% in the last 30 days, moving from a September 8, 2026 close of $15.22 down to roughly $11.14 in early October. The drop came in a concentrated window after the fiscal first-quarter results and leadership announcement on October 8 rather than through steady erosion.
Looking back over the full quarter, the shares started the summer near $12.80, climbed to a 52-week high around $16.29 in late August, then gave back those gains and fell further in October. From what I see, ANGO finished the three-month stretch down roughly 13%, a figure that hides the earlier rally and subsequent reversal.
Factors Behind the Recent 30-Day Move in ANGO
The main driver was the fiscal 2027 first-quarter release on October 8, 2026, covering the period ended August 31. Revenue reached $80.9 million, a 6.9% year-over-year increase and ahead of the roughly $80.5 million consensus. Adjusted loss per share came in at $0.04, better than the expected $0.11 loss, while adjusted EBITDA rose to $5.0 million from $2.2 million.
Even with those beats, the stock fell more than 20% on the day. The company still recorded a GAAP net loss of $7.1 million, or $0.17 per share. Investors also factored in the CEO transition, with Eric Honroth, formerly a senior executive at Getinge, set to take over from Jim Clemmer on November 2, 2026. Gross margin expanded 410 basis points to 59.4%, helped by a $1.2 million tariff refund; without it the margin would have been near 57.8%. Management indicated tariff effects in fiscal 2027 should track those of fiscal 2026.
Quarterly Drivers and Market Reaction
Through July and August the shares advanced on steady Med Tech progress. Auryon posted its 21st straight quarter of double-digit growth, NanoKnife saw record procedure volumes in prostate applications, and mechanical thrombectomy continued to gain traction. The move to the 52-week high near $16.29 reflected optimism around that momentum and expanding reimbursement for NanoKnife. I reviewed the numbers with Tickeron’s AI Trend Prediction Engine to confirm the trends.
September brought consolidation back toward the $15 level, and the October earnings release triggered the sharper reversal. Across the three-month period the underlying Med Tech growth narrative stayed intact, even as attention turned to ongoing GAAP losses, the makeup of margins, and the upcoming leadership change.
Key Items to Monitor for ANGO Going Forward
Investors will focus on the November 2, 2026 CEO transition and any early signals on strategic direction under new leadership. Progress toward making Med Tech the majority of revenue in fiscal 2027, continued Auryon and NanoKnife expansion, and adoption of mechanical thrombectomy remain central themes. Clinical and reimbursement updates, including NanoKnife coverage expansion, the RELIEF study in benign prostatic hyperplasia, the AMBITION BTK study for Auryon, and the AlphaReturn and AngioVac IDE trials, will also matter. Tariff effects on margins and the target of positive operating cash flow for the full fiscal year round out the list of items worth watching.
Exploring AI-Powered Trading Tools
In my own analysis I sometimes reference Tickeron’s curated selection of AI trading bots to compare strategies across different timeframes and market conditions. The Trending AI Robots page highlights top-performing bots that monitor thousands of tickers, giving a practical view of which approaches are drawing attention right now. It serves as a neutral starting point when I want to see how data-driven signals align with the fundamentals I am reviewing.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ANGO in downward trend: 10-day moving average broke below 50-day moving average on October 05, 2026
The 10-day moving average for ANGO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANGO as a result. In 66 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
ANGO moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ANGO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANGO advanced for three days, in 201 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ANGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 126 of 179 cases where ANGO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ANGO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.826) is normal, around the industry mean (5.020). P/E Ratio (44.843) is within average values for comparable stocks, (166.342). Projected Growth (PEG Ratio) (0.110) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.005) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices used by radiologists, vascular surgeons and other physicians
Industry PharmaceuticalsOther
Advertisement